| Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes |
43 |
| Targeting RNA: A Transformative Therapeutic Strategy |
26 |
| Future of Rare Diseases Research 2017-2027: An IRDiRC Perspective |
22 |
| Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy |
20 |
| Progress in Rare Diseases Research 2010-2016: An IRDiRC Perspective |
16 |
| The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and Development |
16 |
| Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation |
12 |
| Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development |
12 |
| Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers |
12 |
| Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin |
11 |
| Drug-Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers |
11 |
| The DILI-sim Initiative: Insights into Hepatotoxicity Mechanisms and Biomarker Interpretation |
10 |
| Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology |
9 |
| Evaluation of Wearable Digital Devices in a Phase I Clinical Trial |
9 |
| Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers |
9 |
| Physician Awareness of Immune Responses to Polyethylene Glycol-Drug Conjugates |
9 |
| LY312 a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles |
9 |
| Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy |
8 |
| Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient Care |
8 |
| Role of CYP3A in Oral Contraceptives Clearance |
8 |
| Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis |
8 |
| Design and Conduct Considerations for First-in-Human Trials |
8 |
| Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor |
7 |
| Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved Drugs |
7 |
| Initial Clinical Experience with AZD a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor |
7 |
| Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups |
7 |
| Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records |
7 |
| Pharmacokinetics of Anakinra in Subjects of Heavier vs. Lighter Body Weights |
6 |
| Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial |
6 |
| Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development |
6 |
| Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: Two Phase I Studies |
6 |
| The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics |
5 |
| Mechanisms of Action and Clinical Development of Elotuzumab |
5 |
| A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies |
5 |
| Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People |
5 |
| Effect of Dose and 5-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone |
5 |
| Assessment of Dermal Absorption of Aluminum from a Representative Antiperspirant Formulation Using a Al-26 Microtracer Approach |
5 |
| Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan |
5 |
| Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned |
5 |
| Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years |
5 |
| Assay Guidance Manual: Quantitative Biology and Pharmacology in Preclinical Drug Discovery |
5 |
| Impact of Insulin Tregopil and Its Permeation Enhancer on Pharmacokinetics of Metformin in Healthy Volunteers: Randomized, Open-Label, Placebo-Controlled, Crossover Study |
4 |
| VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People |
4 |
| Developing Pharmacogenomic Reports: Insights from Patients and Clinicians |
4 |
| Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis |
4 |
| Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development |
4 |
| Translational Development of Microbiome-Based Therapeutics: Kinetics of E-coli Nissle and Engineered Strains in Humans and Nonhuman Primates |
4 |
| Evaluation of Pharmacokinetics and Pharmacodynamics of BI 42 a Novel GlyT1 Inhibitor: Translational Studies |
4 |
| Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship |
4 |
| Effects of Common CYP1A2 Genotypes and Other Key Factors on Intraindividual Variation in the Caffeine Metabolic Ratio: An Exploratory Analysis |
4 |
